Figures
Abstract
Neonates are highly susceptible to infectious diseases and defective antiviral pDC immune responses have been proposed to contribute to this phenomenon. Isolated cord blood pDCs innately responded to a variety of TLR7 and TLR9 dependent viruses, including influenza A virus (IAV), human immunodeficiency virus (HIV) or herpes-simplex virus (HSV) by efficiently producing IFN-α, TNF-α as well as chemokines. Interestingly, following activation by CpGA, but not viruses, cord pDCs tend to survive less efficiently. We found that a hallmark of pDCs in neonates is an extended CD2+pDCs compartment compared to adult pDCs without affecting the antiviral IFN-α response. Within CD2+pDCs, we identified a subpopulation expressing CD5 and responsible for IL-12p40 production, however this population is significantly decreased in cord blood compared to adult blood. Therefore, neonatal pDCs clearly display variation in phenotype and subset composition, but without major consequences for their antiviral responses.
Citation: Zhang X, Lepelley A, Azria E, Lebon P, Roguet G, Schwartz O, et al. (2013) Neonatal Plasmacytoid Dendritic Cells (pDCs) Display Subset Variation but Can Elicit Potent Anti-Viral Innate Responses. PLoS ONE 8(1): e52003. https://doi.org/10.1371/journal.pone.0052003
Editor: Lena Alexopoulou, Centre d'Immunologie de Marseille-Luminy, CNRS-Inserm, France
Received: September 27, 2012; Accepted: October 30, 2012; Published: January 10, 2013
Copyright: © 2013 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from Agence Nationale pour la Recherche (ANR 09-MIEN-017) and has received funding from the French Government's Investissement d'Avenir program, Laboratoire d'Excellence “Integrative Biology of Emerging Infectious Diseases” (grant n°ANR-10-LABX-62-IBEID)). Work in the O.S. lab is also supported by ANRS, Sidaction and Areva Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
How the immune system in early infancy accommodates pathogens is poorly defined and requires assessment to contrive and improve treatments and vaccines [1]. Newborns are considered to have defective innate immunity, possibly due to reduced inflammatory responses of innate cells to Toll-like receptor (TLR) activation [2] and limited or impaired antigen-presenting cell functions [3]. Studies showed an age-dependent maturation of the IL-12/IFN–γ response [4], [5]. In humans, cell intrinsic epigenetic regulation has been shown to impair the capacity of cord monocyte derived DCs (MoDCs) to produce IL-12 in response to LPS [6]. MoDCs also showed a limited IL-12 response to cytomegalovirus (CMV), although efficient T cell responses develop upon congenital CMV infection [7]. Exceptions exist with TLR7/8 agonists potently activating monocytes for TNF-α production [8].
Viral diseases are a major cause of mortality and morbidity in young children [1], and pDCs potently produce antiviral IFN-α in response to viruses mainly via two major innate recognition receptors of viral nucleic acid, TLR7 and TLR9 [9]. Neonatal murine studies indicate that the dendritic cell compartment including pDCs in lymphoid organs is not intrinsically impaired for innate and antigen-presenting cell (APC) functions [10], [11], [12]. However, pDCs isolated from cord blood have been shown to be defective for CpGA/TLR9 activation due to a limited IRF7 nuclear translocation [13], [14]. Fine tuning of different DCs signals vary depending on the pathogen [15], we thus reinvestigated this issue by extending the study of pDC activation by RNA viruses recognized through TLR7, including IAV [16] and HIV [17] and we further analyzed pDC subsets and phenotypes in neonates.
Materials and Methods
Blood and ethics statement
Heparinized cord blood samples processed within 24 h were collected from healthy full-term neonates (gestation time from 37 to 41 weeks) from Maternity Port Royal and Bichat, both in Paris area, between 2007 and 2010. Buffy coats from 18–60 year-old donors were obtained from the EFS. This study was carried out with the approval of Institut Pasteur Review Board qualified for Medical research and the French Regional Ethics Committee CPP IDF IV in agreement with the principles of the declaration of Helsinki. Written consent was obtained from the mother. Ethnic origin of cord blood donors was not available, but as a reference the geographical origins of children born in 2009 in the maternity was as follows : 48% from Europe, 14% from North Africa, 19% from Sub-Saharan Africa, 5% from Asia. Ethnic origin of adult donors was not available, and all blood samples were collected in Paris area.
Media and reagents
Medium was RPMI-1640 with 5–10% fetal calf serum (ICN Biomedicals, Inc.), 5×10−5 M of 2-Mercaptoethanol (Sigma), and antibiotics (penicillin 100 U/ml, streptomycin 100 µg/ml, GIBCO BRL). TLR9 agonists CpGA (2216, 5′-GGGGACGATCGTCGGGGGG-3′) was synthesized by Sigma. Influenza virus strain A/PR8/1976 (H1N1) was from Charles River Laboratories and used as IAV (live) or HI-IAV (heat-inactivated). Stocks of HSV-1 (Shealy) were prepared from supernatants of infected Vero cells cultured in RPMI–2% FCS for 72 h p.i. at an m.o.i. of 0.1 and had a titer of 106 to 107 PFU/ml. For HIV, primary cells were cocultured with infected MT4C5 T cells (105/ml). HI-IAV was obtained by treating the virus at 56°C for 1 hr. IL-3 and GMCSF were from R&D. Antibodies against CD1c, CD2, CD5, CD14, CD20, CD40, CD45RA, CD86, CD123 and HLADR were from eBioscience, BDCA2 and IFN-α from Miltenyi Biotec, IL-12 p40 from BD Biosciences.
Cell purification and analysis
Mononuclear cells (MNC) were separated from granulocytes, erythrocytes, and platelets by gradient fractionation (Lymphoprep Axis-Shield). pDCs were isolated from CBMCs (cord blood mononuclear cells) or adult PBMCs (peripheral blood mononuclear cells) by using anti–BDCA-4 magnetic beads (Miltenyi Biotec) according to the manufacture's protocol. In short, 100 µl magnetic beads were used for 108 cells in a volume of 500 µl buffer (PBS containing 1% fetal calf serum, 2.5 mM EDTA). After incubation at 4°C for 15min, cells were washed and run on autoMACS Pro (Miltenyi Biotec) by using possels program). Enriched pDCs were further sorted as CD123hiCD45RA+ by flow cytometry on FACSAria (BD Biosciences). In general, 2–3×105 and 5–10×105 pDCs were sorted from one cord blood and one buffy coat, respectively. In some experiments, pDCs were further sorted as CD2+ and CD2−. Purified pDCs and subsets were routinely more than 99% pure.
To measure the frequency of pDCs, pDC subsets or their phenotypes, 106 to 3×106 CBMCs or PBMCs were stained and analyzed. Cells were stained with optimally diluted fluorochrome-conjugated antibodies at room temperature for 10 minutes. Then the cells were acquired on CyAn (Beckman Coulter) and analyzed by Flowjo software (Tree Star) with computed compensation. At least 104 pDCs were gated for analysis.
To measure the survival rate of stimulated pDC, purified pDCs stimulated for 24 hrs were washed twice with PBS and stained with Annexin V Apoptosis detection Kit (BD Biosciences) according to the manufacture's instructions. Cells were acquired on CyAn and analyzed as above.
Innate activation and Cytokine Measurement
Fresh WB, 5×105 MNC or 104 purified pDCs were plated in 96-well flat-bottom plates (WB and MNC in a volume of 250 µl) or U-bottom plates (pDCs in a volume of 200 µl) for stimulation. Plasma or supernatants were collected at 24 hrs and kept frozen at −80°C until detection. IFN-α, TNF-α, CCL3 and CCL4 were measured by a Multiplex kit (Luminex assay, Biosource) according to the manufacture's instructions. Briefly, appropriately diluted samples were distributed into 96-well luminex plate and incubated with fluorescent beads which were coated with first antibody recognizing individual cytokine or chemokine for 1 hr at room temperature with shaking (500 RPM). After washing 3 times, secondary biotin antibodies were added and the plate was further incubated at room temperature for 1 hr with shaking (500 RPM). After washing 3 times, streptavidin phycoerythrin was added and incubated for 10 min at room temperature. The plate was washed for another 3 times and the beads were resuspended in running buffer and acquired on a Luminex ×100 machine by using the Starstation software (Applied Cytometry).
Intracellular cytokine analyses
MNCs were stimulated as indicated for 6 hrs, GolgiPlug (BD Biosciences, 1∶1000 dilution) was added in the culture for the last 3 hrs. Cells were harvested, fixed and permeabilized by using the Cytofix/Cytoperm kit (BD Biosciences). Briefly, cells were first fixed in fixation/permeabilization solution for 20 min at 4°C. Following 2 wahsing steps with the permeabilization/washing solution, cells were stained with optimal concentrations of fluorochrome-conjugated antibodies against IFN-α or IL-12 p40 in the permeabilization/washing solution for 30 min at 4°C. After washing 3 times, cells were resuspended in PBS containing 1% fetal calf serum and acquired on CyAn (Beckman Coulter) and analyzed by Flowjo software (Tree Star). At leat 104 targeted cells (for instance, at lease 104 pDCs were acquried from MNCs if pDCs were the target cells.) were acquired for analysis.
Results and Discussion
We first sought to analyze the antiviral IFN-α response of cord blood cells to TLR7 dependent IAV [16] and HIV [17] as well as in response to TLR9 dependent HSV [18] and CpGA activation (Fig. 1). High levels of IFN-α secretion were observed in all conditions for neonatal whole blood and CBMC. No statistical differences were observed between neonatal and adult samples for all virus stimulation, but CpG/TLR9 displayed discrepancies. Neonatal pDCs were shown to be defective for IFN-α response to CpG/TLR9 activation, but these early studies were performed with pDCs of 50% purity [14]. pDCs can be clearly identified by the expression of BDCA4 and BDCA2, as well as the high expression of CD45RA and CD123. Therefore we further investigated functions of cord blood pDCs to >99% purity by magnetic bead enrichement of BDCA4 cells followed by FACS sorting on CD123 and CD45RA expression (Fig. S1) and then exposed these cells to viruses. pDCs purified from adult and neonatal blood responded similarly (Fig. 1A). These IFN-α responses along with the production of TNF-α and chemokines were as efficient as those obtained with adult samples, except for CpGA/TLR9 activation (Fig. 1B). We observed similar IFN-α responses to heat inactivated IAV in adult and neonatal samples tested as WB, MNC and purified pDCs (Fig. 1C). For neonatal whole blood exposed to live IAV, pDCs were mainly responsible for IFN-α secretion, whereas monocyte only poorly contributed to this response (Fig. 2A). Similarly, following depletion of pDCs, but not ofmonocytes, neonatal MNC were strongly impaired or decreased in their capacity to produce IFN-α in response to CpGA, live and HI- IAV (Fig. 2B). Interestingly, all cord blood samples responded to IAV or HIV, whereas several samples were unresponsive to CpGA as observed with both WB and isolated pDC stimulation. Indeed, we observed a lack of cell survival in several neonatal pDCs samples treated with CpGA that was not observed following viral stimulation (Fig. 3A). Non responders and low responders to CpGA for IFN-α (<100 pg/ml) was associated with poor cell survival (Fig. 3A). This phenomenon may come from the defective signaling observed by others [13]. In line with this, cord blood pDC may require stronger signaling to survive which CpGA stimulation cannot fully provide, although this was only observed in about 15% of samples. Any correlation could be made with the mode of birth delivery (natural delivery vs. caesarian), the gestational age at birth, or the sex of the neonate (Fig. S2). Alternatively, some unknown factor(s) related to development may render neonatal pDCs slightly more vulnerable to apoptosis. The underlying mechanism awaits further investigation. Cell survival as well as IFN-α and TNF-α secretion (Fig. 2B) were restored by adding IL-3 [19] or GM-CSF [20] as survival factors. In contrast to previous reports [18], we failed to detect unresponsive pDCs during HSV/TLR9 stimulation, as both neonatal MNC and purified pDCs produced IFN-α to HSV-1 stimulation (Fig. 1A) indicating that the unresponsive phenotype is not associated with a defective TLR9 pathway in cord pDCs. Our results are supported by an earlier report in which both cord blood and fetal liver pDCs responded normally to HSV stimulation by producing high amount of IFN-α [21]. In addition, this report also provided strong evidence that at earlier developmental stage pDCs expressing CD34 already have the capacity to produce IFN-α in response to HSV [21].
Adult or neonatal whole blood (WB) (A and C), mononuclear cells (MNC) (A and C) or purified pDCs (A–C) were stimulated with CpGA (50 µg/ml for WB, 5 µg/ml for others in A), live IAV (1000 HAU/ml for WB, 10 HAU/ml for others), heat-inactivated IAV (HI-IAV in C) live HIV (105 infected T cells in A) and live HSV-1 (106 pfu/ml in A) for 24 hrs. Plasma or supernatants were collected and tested for IFN-α (A and C) or TNF-α, CCL3 and CCL4 (B). NA: non applicable. The number of donors is indicated for each group (n) as well as P values for adults and neonates comparison. In B, n = 8 for adult and n = 7 for neonates.
(A) Neonatal cord blood was left untreated or exposed to IAV, for 6 hrs and stained intracellularly for IFN-α. pDCs are identified by CD123 and BDCA4 and monocytes by CD14 expression. (B) Total CBMC (1), or CBMC depleted of pDCs (2) or of monocytes (3) were stimulated with CpGA, live IAV and HI-IAV as in Fig. Plasma or supernatants were collected and tested for IFN-α (A). Depletion efficiency is shown for pDCs identified by CD123 and CD45RA and monocytes by CD14 and CD11b expression. One experiment representative of three is shown.
(A) IFN-α responses of neonatal pDCs to CpGA were plotted against the survival rate. Cell survival is shown by annexin V and propidium iodide staining (PI). (B) Neonatal pDCs were stimulated with CpGA or IAV in the absence or presence of IL-3 (10 ng/ml) or GMCSF (10 ng/ml) for 24 hrs. IFN-α was detected from supernatants.
Mouse pDCs are clearly described for the production of both IFN-α and IL-12 following TLR7/9 activation by viruses and synthetic agonists. Human pDCs seem to be much more restricted in their antiviral responses by producing IFN-α but not IL-12 [22]. Nevertheless, a small fraction of mature pDC can produce IL12 but not IFN-α [23]. Recently, CD2 was highlighted as a potential marker for human pDCs subsets [24], and CD2+pDCs were shown to produce IL-12p40 in addition to other properties including IFN-α production. Importantly, the frequency of CD2+ and CD2- pDCs differed markedly between neonates and adult (Fig. 4A and B), therefore we assessed the capacity of both subsets to respond to CpGA or IAV and HIV viruses (Fig. 4C and D). Both neonatal and adult pDCs subsets similarly produced IFN-α. Non responders to CpGA was not associated with a particular subset and could respond to HIV and IAV (Fig. 4C). We further investigated IL-12p40 production by CD2+ vs. CD2- pDCs, however we identified among CD2+pDCs that only a minor population expressing CD5 did produce IL-12p40 in response to CpGA and to HI-IAV (Fig. 5A). Steady state CD5+CD2+ pDC produced much less IFN-α following TLR activation as compared to other pDC subsets (Fig. 4D). These results are in agreement with the dichotomy between IFN-α and IL-12 producing cells [23]. Interestingly, CD5+CD2+ pDC at steady state have a mature phenotype with increased CD86 and HLADR expression as compared to other pDCs (Fig. 5B) and thus probably more prone to play antigen-presenting cell functions. Again no difference was observed between neonatal and adult pDCs. IL-12p40 was not induced in myeloid DC and monocytes following CpGA activation (Fig. 5A) in accordance with the lack of TLR 9 expression in these cells [25]. IL-12p70 and IL-23 were not detected in agreement with previous studies [22]. IL-12p40 has been suggested to be a chemoattractant for macrophages in the context of bacterial infection, whether it may play a similar function in viral infection or in antigen-presenting cell related functions of pDCs remains to be clarified [26], [27]. Altogether, these results show that neonatal pDCs potently produce IFN-α in response to live and inactivated viruses. Recent publications highlighted the age dependent maturation of TLR responses [4], [28]. We provide evidence that this is not the case at the level of antiviral responses of isolated pDC and for bulk mononuclear cells for a variety of viruses. This points out the fact that age-dependent maturation may not occur at the level of innate cells, but may rather be controlled at the level of their environment to express optimal functions. Therefore, age-dependent regulatory phenomenon rather than innate deficiencies should be considered for limited inflammatory responses and susceptibility to infections seen in earlylife. We demonstrated that neonatal pDCs can potently participate in innate immunity in the context of viral infection, indicating that pDCs do not contribute to early life susceptibility to infections.
(A) The percentages CD123hiBDCA2+ pDCs within CD45+ MNC were calculated from neonatal cord blood and adults. pDCs could be subdivided by CD2 and CD5, and the accumulated data for CD2+, CD2- pDCs subsets and CD2+CD5+, CD2+CD5− pDCs subsets are shown in (B). (C) The innate IFN-α production of sorted CD2+ and CD2− pDCs subsets to CpGA, live IAV and HIV (the results are incated as ng/ml). (D) Neonatal and Adult MNCs were stimulated as indicated and CD2+CD5+, CD2+CD5− and CD2−CD5− pDCs subsets were gated to analyze their capacity to produce IFN-α detected by intracellular cytokine staining. Numbers indicate the percentage of cytokine-producing cells among gated cells. Data are representative of 5 experiments. The number of donors is indicated for each group (n) as well as P values for adults and neonates comparison.
(A) Neonatal and Adult MNCs were stimulated with IAV-HI CpGA then CD2+CD5+, CD2+CD5− and CD2−CD5− pDCs subsets were gated to analyze their capacity to produce IL-12 p40 detected by intracellular cytokine staining. CpGA stimulated mDC (BDCA1+CD20−CD14−), monocytes (CD14+) and B cells (CD20+) from adult PBMC were also stained for IL-12p40 intracellularly. Numbers indicate the percentage of cytokine-producing cells among totally gated cells. (B) Expression of co-stimulatory markers CD40, CD86 and HLADR on neonatal BDCA4+CD123+pDCs defined as CD2+CD5+, CD2+CD5− and CD2−CD5− subsets under steady state. Data are representative of 3 experiments.
Supporting Information
Figure S1.
pDC phenotype, gating strategy and purity.
https://doi.org/10.1371/journal.pone.0052003.s001
(DOCX)
Figure S2.
IFN-α response to CpG by neonatal MNC or pDCs were compared according to sex, mode of delivery -cesarian (CS) or natural delivery (ND), and gestational age at birth.
https://doi.org/10.1371/journal.pone.0052003.s002
(DOCX)
Acknowledgments
We are very grateful to F. Goffinet (CIC Mère-Enfant) for the cord blood sample collections. This work was supported by grants from Agence Nationale pour la Recherche (ANR 09-MIEN-017) and has received funding from the French Government's Investissement d'Avenir program, Laboratoire d'Excellence “Integrative Biology of Emerging Infectious Diseases” (grant n°ANR-10-LABX-62-IBEID)). Work in the O.S. lab is also supported by ANRS, Sidaction and Areva Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials. We acknowledge the Center for Human Immunology at Institut Pasteur for support in conducting these studies.
The authors have no conflicting financial interest.
Author Contributions
Conceived and designed the experiments: XZ OL GR EA PL GR OS CL RLM. Performed the experiments: XZ AL. Analyzed the data: XZ AL RLM OS. Contributed reagents/materials/analysis tools: GR EA PL OL. Wrote the paper: XZ OL OS RLM.
References
- 1. Prabhudas M, Adkins B, Gans H, King C, Levy O, et al. (2011) Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 12: 189–194.
- 2. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, et al. (2009) Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 183: 7150–7160.
- 3. Adkins B, Leclerc C, Marshall-Clarke S (2004) Neonatal adaptive immunity comes of age. Nat Rev Immunol 4: 553–564.
- 4. Nguyen M, Leuridan E, Zhang T, De Wit D, Willems F, et al. (2010) Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS ONE 5: e10407.
- 5. Upham JW, Lee PT, Holt BJ, Heaton T, Prescott SL, et al. (2002) Development of interleukin-12-producing capacity throughout childhood. Infect Immun 70: 6583–6588.
- 6. Goriely S, Van Lint C, Dadkhah R, Libin M, De Wit D, et al. (2004) A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med 199: 1011–1016.
- 7. Renneson J, Dutta B, Goriely S, Danis B, Lecomte S, et al. (2009) IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection. Eur J Immunol 39: 2789–2799.
- 8. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, et al. (2006) The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 177: 1956–1966.
- 9. Wang Y, Swiecki M, McCartney SA, Colonna M (2011) dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity. Immunol Rev 243: 74–90.
- 10. Sun C, Deriaud E, Leclerc C, Lo-Man R (2005) Upon TLR9 signaling, CD5(+) B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 22: 467–477.
- 11. Zhang X, Deriaud E, Jiao X, Braun D, Leclerc C, et al. (2007) Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med 204: 1107–1118.
- 12. Sun C, Fiette L, Tanguy M, Leclerc C, Lo-Man R (2003) Ontogeny and innate properties of neonatal dendritic cells. Blood 102: 585–591.
- 13. Danis B, George TC, Goriely S, Dutta B, Renneson J, et al. (2008) Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur J Immunol 38: 507–517.
- 14. De Wit D, Olislagers V, Goriely S, Vermeulen F, Wagner H, et al. (2004) Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 103: 1030–1032.
- 15. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, et al. (2008) Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 205: 1447–1461.
- 16. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529–1531.
- 17. Lepelley A, Louis S, Sourisseau M, Law HKW, Pothlichet J, et al. (2011) Innate sensing of HIV-infected cells. PLoS Pathog 7: e1001284.
- 18. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A (2003) Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 198: 513–520.
- 19. Gold MC, Donnelly E, Cook MS, Leclair CM, Lewinsohn DA (2006) Purified neonatal plasmacytoid dendritic cells overcome intrinsic maturation defect with TLR agonist stimulation. Pediatr Res 60: 34–37.
- 20. Ghirelli C, Zollinger R, Soumelis V (2010) Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid predendritic cells. Blood 115: 5037.
- 21. Blom B, Ho S, Antonenko S, Liu YJ (2000) Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 192: 1785–1796.
- 22. Ito T, Kanzler H, Duramad O, Cao W, Liu YJ (2006) Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 107: 2423–2431.
- 23. Duramad O, Fearon KL, Chan JH, Kanzler H, Marshall JD, et al. (2003) IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 102: 4487–4492.
- 24. Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu C-I, et al. (2009) CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 182: 6815–6823.
- 25. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, et al. (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194: 863–869.
- 26. Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE, et al. (2006) Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 177: 1416–1420.
- 27. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, et al. (2006) Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 203: 1805–1815.
- 28. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, et al. (2010) Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS ONE 5: e15041.